Address: LG Twin Towers, 20 Yoido dong, Youngdungpo-gu, Seoul,Republic of Korea
Tel: +82 2 3773 7009
Web: http://www.lgls.com/
In August 2002, LG Life Sciences was upgraded from a business division to a full-fledged LG affiliate in order to grow as a life sciences specialist and maximize shareholder value. LG Life Sciences began research in genetic engineering in 1981 and has invested steadily in the life sciences ever since. This effort has already resulted in world-class technology and product capabilities. The company has focused R&D resources and know-how on three areas-pharmaceuticals, animal health and specialty chemicals. LG Life Sciences has developed and commercialized an array of pharmaceuticals over the years. These include interferon in 1989 (Intermax-gamma) and 1992 (Intermax-alpha), hepatitis B vaccine in 1992 (EUVAX B™), human growth hormone in 1993 (EUTROPIN™), degenerative arthritis treatment in 2005 (HYRUAN Plus™), rhFSH (recombinant human follicle stimulating hormone) in 2006 (Follitrope™), and SR-hGH (Sustained Release-human Growth Hormone) in 2007 (Declage™). A company milestone was reached in 2003, when its next-generation quinolone antibiotic (FACTIVE®) was approved by the FDA in the United States. LG Life Sciences has succeeded in animal health products including the 1994 commercialization of recombinant bovine somatotropin (BST, product name BOOSTIN®). The product, which is used to increase milk production in lactating dairy cows, has achieved the top share in numerous national markets. In 2006, LG Life Sciences has also launched a bovine mastitis vaccine (MastaVac) that reduces the number of somatic cells, relieving clinical symptoms in a cow that has been infected with mastitis. As for specialty chemicals, LG Life Sciences completed in-house development of Republic of Korea’s first new herbicide (PYANCOR®) for rice in 1997 and fungicide (GUARDIAN®) for use in horticulture in 1999. A new herbicide (FLUXO®) for both pre- and post-emergence rice was completed in 2004.
LG Life Sciences has a vision to become a ‘top-tier life sciences company with world-class new drugs’. To this end, LGLS is expanding its strategic alliances and fostering its capabilities to identify candidate drugs for development. Indeed, the company’s development of new medicines is accelerating and marketing competencies are being focused on advanced markets. In the future, LG Life Sciences will remain a leader in life sciences and biotechnology-value added areas that are knowledge intensive.
LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son,…
LG Life Sciences seems quite unique among the rest of pharmaceutical companies in Korea which tend to be family owned. How has this set LGLS apart in terms of its…
A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning technology for treatments that attack cancer cells. Treatments that travel through the…
From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the…
Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…
Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong…
Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia…
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently…
The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303…
Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However,…
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
See our Cookie Privacy Policy Here
